Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital.

ABSTRACT: O⁶-methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital. Surprisingly, methylation of MGMT promoter did not predict response to temozolomide in patients with glioblastoma in Donostia Hospital. Specifically, overall survival (OS) and progression-free survival (PFS) did not differ significantly by MGMT methylation status in our cohort. In contrast, both were longer in patients who received treatment, received more TMZ cycles, had a better general status and perform at least a partial resection. No association was detected between methylation of

SUBMITTER: Egana L 

PROVIDER: S-EPMC7595088 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature